All In Biotech

Drug Trial Radar · NCT05556824

Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD

A Multi-Center Study of Panosyl-Isomaltooligosaccharides (PIMO) Adjunctive to Proton Pump Inhibitor (PPI) Therapy to Treat Gastroesophageal Reflux Disease (GERD) in Subjects Who Are PPI-Responders or PPI-Partial Responders

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 255 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

255

Actual

Start

Mar 3, 2023

Primary completion

May 27, 2026

Study completion May 27, 2026

Sponsor

Lead sponsor
Microbiome Health SciencesIndustry
Sponsor type
Industry
Collaborators
VBHRC Virginia Catalyst
First posted
Sep 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted as a multi-center, randomized, double-blind, placebo-controlled trial to evaluate the effect of MHS-1031 on heartburn-free days in subjects with GERD-related heartburn symptoms.

Conditions

  • Gastroesophageal Reflux

Interventions

  • MHS-1031Drug

    Study medication will be supplied as a syrup in individual sachets containing 1g (1.5 mL) of MHS-1031. Subjects will be randomized in 2:1 fashion to either study drug (2) or placebo (1)

  • PlaceboOther

    Matching placebo is an oral solution formulated to have a degree of sweetness and acidity similar to the study medication and will be provided in equivalent sachets containing 1.5g (1.5 mL) of the oral placebo solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Heartburn-free days/weekTime frame: 4 and 8 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • Elite Clinical Studies LLC

    Phoenix, Arizona

  • Angel City Research

    Los Angeles, California

  • Wr-Msra, Llc

    Lake City, Florida

  • A Positive Clinical Research

    Miami, Florida

  • Advanced Gastroenterology Associates LLC

    Palm Harbor, Florida

  • Health Synergy Clinical Research

    West Palm Beach, Florida

  • West Palm Quality Research (WPQR)

    West Palm Beach, Florida

  • EmVenio-Georgia (EMGA)

    Atlanta, Georgia

  • WR-Mount Vernon Clinical Research (MVCR)

    Sandy Springs, Georgia

  • Gastroenterology Associates of Western Michigan PLC (WMCR)

    Wyoming, Michigan

  • M3 Wake Research (CPOR)

    Raleigh, North Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • SMS Clinical Research (SMSR)

    Mesquite, Texas

  • A and U Family Medicine (NCR)

    Sugar Land, Texas

  • University of Virginia Health System

    Charlottesville, Virginia

  • Charlottesville Medical Research Center

    Charlottesville, Virginia

  • Digestive Disease and Liver Specialists

    Norfolk, Virginia

  • GI Research Partners, LLC

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.